Basics of immunotherapy for epithelial ovarian cancer

Bund, Virginie; Azaïs, Henri; Bibi-Triki, Sabrina; Lecointre, Lise; Bétrian, Sarah; Ángeles, Martina Aida; Eberst, Lauriane; Faller, Émilie; Boisramé, Thomas; Bendifallah, Sofiane; Akladios, Chérif; Deluche, Élise

doi:10.1016/j.jogoh.2021.102283

Cited by 6 publications

(1 citation statement)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immune checkpoint inhibitors have demonstrated remarkable effectiveness in treating various types of cancer with superior results compared to conventional therapies [as shown in Table ]. Nine α-PD-1 (nivolumab, pembrolizumab, cemiplimab, carrizumab, topalizumab, tilelizumab, simepilimumab, pegolimab, and dostarlimumab) and three α-PD-L1 antibodies, including atezolizumab, durvalumab, and avelumab, have been granted approval for the treatment of various types of cancer, such as lung, melanoma, and kidney cancers, leading to significant improvement in patient survival . Scientists believe that immune checkpoint inhibitors may also provide benefits to patients with ovarian cancer, which is known to be an immunosuppressive type of tumor …”

Section: Passive Immunotherapymentioning

confidence: 99%

Immunotherapy for Ovarian Cancer: Disappointing or Promising?

Deng,

Tang,

Chang

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

Ovarian cancer, one of the deadliest malignancies, lacks effective treatment, despite advancements in surgical techniques and chemotherapy. Thus, new therapeutic approaches are imperative to improving treatment outcomes. Immunotherapy, which has demonstrated considerable success in managing various cancers, has already found its place in clinical practice. This review aims to provide an overview of ovarian tumor immunotherapy, including its basics, key strategies, and clinical research data supporting its potential. In particular, this discussion highlights promising strategies such as checkpoint inhibitors, vaccines, and pericyte transfer, both individually and in combination. However, the advancement of new immunotherapies necessitates large controlled randomized trials, which will undoubtedly shape the future of ovarian cancer treatment.

show abstract

Section: Passive Immunotherapymentioning

confidence: 99%